Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY:CYBN)

8.645 -0.065 (-0.74%)
Streaming Delayed Price Updated: 10:11 AM EDT, Jun 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
39 40 Next >
Psychedelic Stock Gainers And Losers From February 21, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From February 20, 2023
Via Benzinga
"Multi-Bagger" Portfolio Outperforming "Rags-To-Riches" Portfolio YTD By A 2-To-1 Margin
Cannabis, psychedelic and plant-based food stocks were extremely oversold in 2022. Perhaps some will bounce back with 
Via Talk Markets
6 Largest Psychedelic Stocks Showing Strength; Up 11.5% YTD
A look at the performance of the six largest psychedelic stocks by market capitalization. 
Via Talk Markets
ATAI Life Sciences, GH Research Among Top Psychedelic Movers Of Today
Via Benzinga
Cybin, Compass Pathways Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From February 15, 2023
Via Benzinga
GH Research, Mind Medicine Among Top Psychedelic Movers Of Today
Via Benzinga
Cybin Reports Q3 Earnings, Says Psilocybin Tial Is Progressing As MDD Treatment
Cybin Inc. (NYSE: CYBN) has shared its unaudited financial results for the third quarter that ended Dec. 31, 2022. The company held total cash of $16.9 (CA$22.5) million as of Dec. 31, 2022, and $15... 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Q3 Financial Report, Corporate Highlights
Via Investor Brand Network
Cybin Inc. Reports Third Quarter Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Mind Medicine, GH Research Among Top Psychedelic Movers Of Today
Via Benzinga
"Multi-Bagger" Portfolio Update
Cannabis, psychedelic and plant-based food stocks were extremely oversold in 2022. I'm tracking 12 microcap stocks that might bounce back with major returns - dare I say 
Via Talk Markets
Major Psychedelic Compound-Based Stocks UP 13% YTD
We track the performance of the 6 largest companies researching the treatment of mental illnesses based on the use of one or more of 10 different psychedelic compound-based substances. 
Via Talk Markets
Cybin, Seelos Therapeutics Among Top Psychedelic Movers Of Today
Via Benzinga
Seelos Therapeutics, Cybin Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From February 8, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From February 7, 2023
Via Benzinga
The "Multi-Bagger" Portfolio Continued To Outperform The S&P 500 Last Week
Our basket of mostly microcap cannabis, psychedelic and plant-based food stocks was extremely oversold in 2022 but we're watching for them to bounce back in 2023. 
Via Talk Markets
Mind Medicine, GH Research Among Top Psychedelic Movers Of Today
Via Benzinga
The 7 Most Promising Psychedelic Stocks to Buy in February
These psychedelics stocks to buy belong to pre-revenue firms which could potentially blow-up in line with the burgeoning sector. 
Via InvestorPlace
6 Largest Psychedelic Stocks Down 3% This Week
The six largest of the 40 companies researching the treatment of mental illnesses by using psychedelic substances, which constitute our Psychedelic Drug Stocks Index, are now up 13% YTD despite a loss... 
Via Talk Markets
Psychedelic Stock Gainers And Losers From February 3, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From February 2, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From February 1, 2023
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Approval for First-in-Human Dosing of Proprietary DMT Molecule
Via Investor Brand Network
Cybin Approved For First In-Human Dosing Of DMT Molecule CYB004, Milestone For Anxiety Disorder Treatment
Cybin Inc. (NYSE: CYBN) announced that it has received approval from an independent ethics committee in the Netherlands to begin the first in-human dosing of its proprietary deuterated... 
Via Benzinga
Cybin Announces Approval of First-in-Human Dosing of its Proprietary DMT Molecule CYB004
From Cybin Inc.
Via Business Wire
GH Research, Mind Medicine Among Top Psychedelic Movers Of Today
Via Benzinga
Intelgenx Technologies, Cybin Among Top Psychedelic Movers Of Today
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
39 40 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.